Moreover, comparisons of baseline characteristics between patients with low BMI (≤ 25) or not in DPP4i (+) and (−) groups found that patients with low BMI were older and not likely to have dyslipidemia and there was a significant deference in the concomitant use of SGLT-2 inhibitor with DPP4i between groups with BMI > 25 and ≤ 25 (Supplementary Table 1). This evidence concerns the gene SLC5A2 and metabolic syndrome.